Lyme disease, caused by Borrelia burgdorferi and transmitted by ticks, was initially considered a recent, rare and regional occurrence. We now have evidence that very similar bacteria infected humans in Europe during the ice age (Keller et al., 2012). Evidence-based data are scarce therefore many aspects of the disease remain controversial (Auwaerter et al., 2011; Lee and Vielmeyer, 2011; Perronne, 2012), but in 2013 the Centers for Disease Control and Prevention (CDC) revised their annual estimates from 30,000 cases to 300,000 cases in the USA alone. Having dramatically increased their numbers, the CDC are now calling Lyme disease “a tremendous public health problem in the United States” (CDC, 2011).
The lack of a gold standard for diagnosis makes producing accurate statistics difficult. Some pathogenic strains belonging to the B. burgdorferi sensu lato complex have a worldwide distribution, yet they are rarely considered or tested for (Varela et al., 2004; Lopes de Carvalho et al., 2009; Rudenko et al., 2009; Stanek and Reiter, 2011; Branda and Rosenberg, 2013; Clark et al., 2013; Lee et al., 2014; Margos et al., 2014). Borrelia miyamotoi, for instance, phylogenetically close to relapsing fever borreliae, is now recognized as a cause of Lyme-like disease and relapsing fever in Asia, Europe and North America. It usually does not cross react with B. burgdorferi tests (Branda and Rosenberg, 2013; Lee et al., 2014). A novel isolate of Borrelia has been isolated by PCR in a post-treatment serum from a patient with neurologic Lyme disease (Lee et al., 2014).
These recent historical, geographical and microbial data should prompt the medical community to realize that cases of persisting post tick-bite syndromes are probably due to multiple pathogens and that these occult infections will require a new approach if not an actual paradigm shift.
Diagnostic pitfalls in routine practice
Classical forms of Lyme disease are usually easy to manage, but these medical conditions with pleomorphic non specific symptoms may prove confusing to physicians (Strle and Stanek, 2009). Lyme disease may mimic chronic inflammatory or degenerative diseases, including a wide range of auto-immune diseases. Although practitioners from every medical specialty are likely to have encountered cases of Lyme disease, they may have failed to recognize it, no matter how skilled they are. A major obstacle is that only 30% of the patients report a history of tick bite and only 70–80% present with a primary erythema migrans, the pathognomonic initial lesion. This lesion may go unrecognized, or be mistaken for an “insect bite” or an “allergic rash.” Mini-erythema migrans are less likely to be diagnosed. Secondary erythema migrans are observed in approximately 50% of cases. Bacteriologic and pathologic analogies have been reported between tertiary neuroborreliosis and tertiary neurosyphilis (Miklossy, 2012). Syphilis, once well-known as the great imitator, gives us a good historical model for the concept of occult infection.
Occult infections and their role in the pathophysiology of some diseases of unclear etiology
Charles Nicolle, working at the Institut Pasteur in Tunis and Nobel prize winner in 1928, showed great interest in the concept of occult infections (“les infections inapparentes”) like typhus, syphilis, and relapsing fever (Borrelia recurrentis) (Nicolle, 1993). Relapsing fever due to another species of Borrelia (B. crocidurae) is still a public health concern in some parts of Africa, and the recently discovered B. miyamotoi may also become a similar problem in Asia, Europe and America (Schwan et al., 2012; Branda and Rosenberg, 2013; Lee et al., 2014). Peptic ulcer disease is another example of the hidden link between an occult infection with another spiral-shaped bacterium, Helicobacter pylori, and a chronic disorder. B. burgdorferi may persist in tissues even after antibiotic treatments, as animal models have shown (Straubinger et al., 1997; Straubinger, 2000; Hodzic et al., 2008; Yrjänäinen et al., 2010; Embers et al., 2012). In fact dormant persister cells of bacteria from different genera can escape the bactericidal effect of antibiotics and be responsible for latent infections (Phillips et al., 1998; Hunfeld et al., 2005; Lewis, 2007; Lee et al., 2014). Clinicians have no diagnostic tests to check for the persistence of live borreliae. B. burgdorferi, having a complex genetic structure, is a highly adaptable organism capable of evading immune response through different processes. It can survive extracellularly and intracellularly (Brorson and Brorson, 1998; Murgia and Cinco, 2004). The complexity of Lyme disease requires high quality diagnostic methods, yet serology is the only diagnostic tool widely used.
Serology, the current main diagnostic method
Physicians should be made aware that, in the presence of primary erythema migrans, serology will often be negative therefore diagnosis should be clinical (Wormser, 2006). However, many practitioners are still under the misconception that a positive serology is required for early stage diagnosis. For later stages of the disease serology remains the main diagnostic tool. The Infectious Diseases Society of America (IDSA) and the European Concerted Action on Lyme Borreliosis (EUCALB) are recommending a two-tier testing approach, the first step being an ELISA using whole sonicate of the in vitro cultured tick-derived strain B31 of Borrelia burgdorferi (EUCALB, 1997; Wormser et al., 2006). If positive, confirmation by immunoblot testing IgG and IgM is required. According to these guidelines, immunoblot is not to be performed if the ELISA is negative. However, in 2011, the CDC modified their case definition and included single-tier IgG immunoblot seropositivity as a diagnostic criterion for Lyme disease (CDC, 2013). But most practitioners still use the two-tier system despite the poor sensitivity of ELISA tests, ranging from 34 to 70.5 (Marangoni et al., 2005; Aguero-Rosenfeld, 2008; Ang et al., 2011; Wojciechowska-Koszko et al., 2011). Calibration of the tests is a crucial issue.
Calibration of serology
When Lyme serology was developed, no reliable method was available to be used as a gold standard for comparison. As most of the signs and symptoms are non-specific, no reliable clinical diagnostic score could be established. The low yield of culture and the difficulty involved in using the technique routinely were another major obstacle. A pragmatic cut-off level for the serologic tests had to be determined arbitrarily on blood donors (EUCALB, 1997; Assous, 2007). In the late seventies, when Lyme disease was first discovered, it was understandably thought to be a rare and regional phenomenon. Therefore, a low prevalence was set as experts were afraid the serologies would produce too many false positive diagnoses (EUCALB, 1997; Assous, 2007). Patients and control populations are ill-defined with a high variability in predictive positive and negative values from one test to another. Culture of B. burgdorferi or detection of its genome by polymerase chain reaction (PCR) may occasionally confirm the clinical diagnosis in seronegative patients, however none of these methods are sensitive enough to be considered reliable diagnostic methods, especially in routine practice (Schutzer et al., 1990; Nields and Kveton, 1991; Chmielewska-Badora et al., 2006; Brunner, 2006; Assous, 2007; Holl-Wieden et al., 2007; Aguero-Rosenfeld, 2008; Dietrich et al., 2008; Wallet et al., 2008). As a result, many patients suffering signs and symptoms compatible with Lyme disease, but whose test is negative, are falling by the wayside.
Clinical and epidemiological consequences of negative serology
Modern medical practice expects to rely on evidence. Most physicians would not consider diagnosing Lyme disease without serological proof. Yet the failure to diagnose seronegative neuroborreliosis, especially the acute or severe forms, can have dire consequences including chronic neurologic sequelae or even death. A review of the literature shows that a diagnosis of Lyme neuroborreliosis is often difficult to prove (Blanc et al., 2007; Bennet et al., 2008; Tveitnes et al., 2009; Makhani et al., 2011). The sensitivity of intrathecal antibody index (measuring specific antibodies within the cerebro-spinal fluid) ranges from 55 to 80%. In a Swedish study, antibodies were present in serum of only 23% of children with neuroborreliosis (Bennet et al., 2008). Cognitive tests or SPECT brain imaging may help to provide objective evidence (Tager et al., 2001; Roche-Lanquetot et al., 2008; Fallon et al., 2009; Donta et al., 2012). Pragmatic diagnostic criteria including response to empiric antibiotic treatment are used to diagnose neuroborreliosis (Blanc et al., 2007). Should this strategy be recommended in other clinical presentations as well? In fact some clinicians will not hesitate to classify as Lyme disease cases, seronegative patients with a highly compatible clinical picture, provided other diagnoses have been ruled out. In a major clinical trial on Lyme disease, 40% of the enrolled patients were seronegative. These patients had a history of erythema migrans, neurologic or cardiac symptoms, radiculoneuropathy or arthritis (Klempner et al., 2001). Clinicians, often unaware of the difficulties involved in diagnosing Lyme disease, will fall back on “weak” alternative diagnoses (“viral,” “idiopathic,” “auto-immune,” “degenerative,” “inflammatory,” or “psychosomatic”) (Kennedy, 2013). New techniques are needed to accurately assess these patients. This current over-reliance on inaccurate testing procedures not only flaws the diagnosis of individual patients but it also has epidemiological consequences especially as new species and variants continue to be identified on all continents (Hao et al., 2011; Rudenko et al., 2011).
Possible causes of seronegativity
Several factors leading to seronegativity have been identified in confirmed cases of Lyme disease: (i) the arbitrary cut-off level of tests, (ii) the sequestration of antibodies in immune complexes, (iii) the wide variety of species and subspecies of Borrelia that co-exist in different parts of the world, and (iv) coinfections with other pathogens which may be responsible for some or all of the symptoms or which may alter the immune response (Schutzer et al., 1990; Brunner, 2006). The complex B. burgdorferi sensu lato includes (Table 1): B. burgdorferi sensu stricto (including genetic diversity), B. afzelii, B. garinii (several serotypes) and additional species isolated in different parts of the world (Rudenko et al., 2009, 2011; Ogden et al., 2011). Some of these species have been isolated in symptomatic patients (Varela et al., 2004; Lopes de Carvalho et al., 2009; Rudenko et al., 2009; Stanek and Reiter, 2011; Branda and Rosenberg, 2013; Clark et al., 2013; Lee et al., 2014; Margos et al., 2014). B. spielmanii may cause early skin disease (Stanek and Reiter, 2011). B. bavariensis, B. bisettii, B. valaisiana, B. americana, B. andersonii, B. lonestari and more recently B. kurtenbachii have been isolated from patients with Lyme-like diseases (Varela et al., 2004; Rudenko et al., 2009; Rizzoli et al., 2011; Stanek and Reiter, 2011; Clark et al., 2013). The pathogenic role of B. lusitaniae, isolated in a case of vasculitis, remains to be substantiated (Rudenko et al., 2009). Despite such diversity in strains, most of the commercially available tests still rely on the original 1982 Massachusetts B31 isolate of B. burgdorferi. No diagnostic tool is available for routine detection of B. miyamotoi (Branda and Rosenberg, 2013; Lee et al., 2014). Coinfections with other microbes add to the complexity of these illnesses (Table 1). Among patients with early Lyme disease in the USA, 2–12% were found to also have human granulocytic anaplasmosis, and 2–40% babesiosis (Wormser et al., 2006). In Brazil, a Lyme-like syndrome, due to the tick Amblyomma, has been described and mobile non cultivable spirochetes could be visualized in patients' blood using a dark field microscope (Mantovani et al., 2007). A new tick-borne bacterial pathogen, Candidatus Neoehrlichia mikurensis, was reported in Switzerland (Fehr et al., 2010). An illustration of the limits of serology is the Scottish example: the sensitivity of the immunoblot was improved by using local Scottish strains of Borrelia (Mavin et al., 2007, 2009).
Table 1
| Bacteria responsible for Lyme disease belonging to the Borrelia burgdorferi sensu lato complex | |
| Borrelia burgdorferi sensu stricto (including genetic diversity) | North America, Europe, North Africa |
| Borrelia afzelii | Europe, Asia |
| Borrelia garinii (several serotypes) | Europe, Asia, North Africa |
| Borrelia bavariensis (previously B. garinii OspA serotype 4) | |
| Bacteria responsible for Lyme-like disease | |
| Borrelia lonestari | North America |
| Borrelia miyamotoi (also cause of relapsing fever) | Europe, Asia, North America |
| Non-identified spirochete | Brazil |
| Bacteria occasionally isolated in cases of Lyme-like disease | |
| Borrelia spielmanii | Borrelia bisettii |
| Borrelia andersonii | Borrelia valaisiana |
| Borrelia americana | Borrelia kurtenbachii |
| Novel Borrelia sp. close to relapsing fever borreliae (Lee et al., 2014) | |
| Other Borrelia sp., belonging to the Borrelia burgdorferi sensu lato complex with unknown or poorly documented pathogenicity | |
| Borrelia japonica | Borrelia turdi |
| Borrelia sinica | Borrelia tanukii |
| Borrelia lusitaniae (vasculitis?) | Borrelia californiensis |
| Borrelia carolinensis | Borrelia yangtze |
| Borrelia sp. responsible for relapsing fever | |
| Louse-borne relapsing fever | |
| Borrelia recurrentis | |
| Tick-borne relapsing fever | |
| At least 15 Borrelia sp. including | |
| Borrelia crocidurae (Africa) | |
| Borrelia miyamotoi (also cause of Lyme-like disease) | |
| Other human tick-borne infections | |
| PARASITES | |
| Babesia divergens | Babesia microti |
| BACTERIA | |
| Ehrlichia chaffeensis | Anaplasma phagocytophilum |
| Rickettsia sp. | Coxiella burnetii |
| Francisella tularensis | Candidatus Neoehrlichia mikurensis |
| VIRUSES | |
| Several Flaviviridae (including Tick-borne encephalitis virus) | |
| Bunyaviridae (Crimean-Congo hemorrhagic fever) | |
Bacteria responsible for Lyme or Lyme-like disease and other Borrelia sp. belonging to the Borrelia burgdorferi sensu lato complex, and other tick-borne micro-organisms isolated in humans.
Conclusion and perspectives
The numerous complexities of Lyme disease make it an extremely difficult illness to fully comprehend. It remains a diagnostic challenge even for the best informed of clinicians. The lack of a gold standard for diagnosis renders the management of patients difficult and seriously hinders our ability to produce accurate statistics, especially as very similar syndromes could be due to other species of Borrelia. In some patients suffering from syndromes of unclear origin, following tick bite, other microbial agents could also be playing a role. Lyme disease has now entered the political debate as shown by the amendment (Section 54.1-2963.2) voted in 2013 by the State of Virginia, USA, that compels physicians to inform their patients that the “current laboratory testing for Lyme disease can be problematic.” The fact that politicians are being called upon to rule on these matters should prompt scientists to regain control of the situation. Politicians should instead become aware of the necessity to fund research and facilitate the setting up of independent international working groups. Reliable testing is essential to investigate the many syndromes of unclear origin that may mimic many other medical disorders. Proper fundamental and clinical research is urgently needed as it would be the most cost effective way of ensuring that patients are accurately diagnosed and that the best therapeutic strategies are decided upon (Stricker and Johnson, 2014). Development of new diagnostic methods is badly needed. New PCR methods and new genomic techniques, such as high throughput sequencing, could prove promising in identifying the complex mix of microbial agents that are probably involved (Vayssier-Taussat et al., 2013; Lee et al., 2014). Next generation sequencing allowed the identification of various bacteria from Ixodes ricinus ticks in France: Anaplasma phagocytophilum, Bartonella henselae, B. grahamii, Borrelia afzelii, B. garinii, B. burgdorferi, B. miyamotoi, Candidatus Neoerlichia mikurensis, Ehrlichia canis, Rickettsia canadensis, R. felis, and R. helvetica (Vayssier-Taussat et al., 2013). These new techniques should be applied to human samples. Other variables, such as genetic, environmental, or auto-immune factors should also be studied. The name “Lyme disease” is too restrictive as it focuses and fuels the controversy. A new term should be agreed upon for these syndromes with possible infectious involvement, often following tick bites. Closer collaboration between epidemiologists, microbiologists, immunologists, geneticians, environmental scientists, veterinarians, entomologists, and clinicians is needed to identify the main agents that could be causing these occult infections and to determine strain pathogenicity. A new multidirectional approach is crucial in order to widen the field of research and to move forward.
Conflict of interest statement
The author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Statements
Acknowledgments
The author thanks Nelly Pointis for her help with editing.
Conflict of interest
The author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
1
Aguero-RosenfeldM. E. (2008). Lyme disease: laboratory issues. Infect. Dis. Clin. North Am. 22, 301–313. 10.1016/j.idc.2007.12.005
2
AngC. W.NotermansD. W.HommesM.Simoons-SmitA. M.HerremansT. (2011). Large differences between test strategies for the detection of anti-Borrelia antibodies are revealed by comparing eight ELISAs and five immunoblots. Eur. J. Clin. Microbiol. Infect. Dis. 30, 1027–1032. 10.1007/s10096-011-1157-6
3
AssousM. V. (2007). Laboratory methods for the diagnosis of clinical forms of Lyme borreliosis (in French). Med. Mal. Infect. 37, 487–495. 10.1016/j.medmal.2006.01.019
4
AuwaerterP. G.BakkenJ. S.DattwylerR. J.DumlerJ. S.HalperinJ. J.McSweeganE.et al. (2011). Antiscience and ethical concerns associated with advocacy of Lyme disease. Lancet Infect. Dis. 11, 713–719. 10.1016/S1473-3099(11)70034-2
5
BennetR.LindgrenV.Zweygberg-WirgartB. (2008). Borrelia antibodies in children evaluated for Lyme neuroborreliosis. Infection36, 463–466. 10.1007/s15010-008-6259-4
6
BlancF.JaulhacB.FleuryM.de SèzeJ.de MartinoS. J.RémyV.et al. (2007). Relevance of the antibody index to diagnose Lyme neuroborreliosis among seropositive patients. Neurology69, 953–958. 10.1212/01.wnl.0000269672.17807.e0
7
BrandaJ. A.RosenbergE. (2013). S. Borrelia miyamotoi: a lesson in disease discovery. Ann. Intern. Med. 159, 61–62. 10.7326/0003-4819-159-1-201307020-00009
8
BrorsonO.BrorsonS. H. (1998). In vitro conversion of Borrelia burgdorferi to cystic forms in spinal fluid, and transformation to mobile spirochetes by incubation in BSK-H medium. Infection26, 144–150. 10.1007/BF02771839
9
BrunnerM. (2006). Report refuting value of immune complexes to diagnose Lyme disease is invalid. Clin. Vaccine Immunol. 13, 304–306. 10.1128/CVI.13.2.304-306.2006
10
CDC. (2011). Centers for Disease Control and Prevention. National notifiable Diseases Surveillance System. Lyme disease - Borrelia Burgdorferi - 2011 Case Definition. Available online at: wwwn.cdc.gov/NNDSS/script/casedef.aspx (Accessed March 24, 2014).
11
CDC. (2013). Centers for Disease Control and Prevention. Media Relations. CDC Provides Estimate of Americans Diagnosed with Lyme Disease Each Year. Available online at: www.cdc.gov/media/releases/2013/p0819-lyme-disease.html (Accessed March 24, 2014).
12
Chmielewska-BadoraJ.CisakE.Wojcik-FatlaA.ZwolinskiJ.BuczekA.DutkiewiczJ. (2006). Correlation of tests for detection of Borrelia burgdorferi sensu lato infection in patients with diagnosed borreliosis. Ann. Agric. Environ. Med. 13, 307–311.
13
ClarkK. L.LeydetB.HartmanS. (2013). Lyme borreliosis in human patients in Florida and Georgia, USA. Int. J. Med. Sci. 10, 915–931. 10.7150/ijms.6273
14
DietrichT.GeissdörferW.Schlötzer-SchrehardtU.HolbachL.SchoernerC.SeitzB. (2008). Borrelia-associated crystalline keratopathy with intracorneal detection of Borrelia garinii by electron microscopy and polymerase chain reaction. Cornea27, 498–500. 10.1097/ICO.0b013e318162a8f5
15
DontaS. T.NotoR. B.VentoJ. A. (2012). SPECT brain imaging in chronic Lyme disease. Clin. Nucl Med37, 219–222. 10.1097/RLU.0b013e318262ad9b
16
EmbersM. E.BartholdS. W.BordaJ. T.BowersL.DoyleL.HodzicE.et al. (2012). Persistence of Borrelia burgdorferi in Rhesus macaques following antibiotic treatment of disseminated infection. PLoS ONE7:e29914. Erratum PLoS ONE 7. 10.1371/journal.pone.0029914
17
EUCALB. (1997). European Concerted Action on Lyme Borreliosis, Diagnosis: Serology: Minimum Standards. Available online at: www.eucalb.com (Accessed March 24, 2014).
18
FallonB. A.LipkinR. B.CorberaK. M.YuS.NoblerM. S.KeilpJ. G.et al. (2009). Regional cerebral blood flow and metabolic rate in persistent Lyme encephalopathy. Arch. Gen. Psychiatry66, 554–563. 10.1001/archgenpsychiatry.2009.29
19
FehrJ. S.BloembergG. V.RitterC.HombachM.LüscherT. F.WeberR.et al. (2010). Septicemia caused by tick-borne bacterial pathogen Candidatus Neoehrlichia mikurensis. Emerging Infect. Dis. 16, 1127–1129. 10.3201/eid1607.091907
20
HaoQ.HouX.GengZ.WanK. (2011). Distribution of Borrelia burgdorferi sensu lato in China. J. Clin. Microbiol. 49, 647–650. 10.1128/JCM.00725-10
21
HodzicE.FengS.HoldenK.FreetK. J.BartholdS. W. (2008). Persistence of Borrelia burgdorferi following antibiotic treatment in mice. Antimicrob. Agents Chemother. 52, 1728–1736. 10.1128/AAC.01050-07
22
Holl-WiedenA.SuerbaumS.GirschickH. J. (2007). Seronegative Lyme arthritis. Rheumatol. Int. 27, 1091–1093. 10.1007/s00296-007-0333-6
23
HunfeldK. P.Ruzic-SabljicE.NorrisD. E.KraiczyP.StrlF. (2005). In vitro susceptibility testing of Borrelia burgdorferi sensu lato isolates cultured from patients with erythema migrans before and after antimicrobial chemotherapy. Antimicrob. Agents Chemother. 49, 1294–1301. 10.1128/AAC.49.4.1294-1301.2005
24
KellerA.GraefenA.BallM.MatzasM.BoisguerinV.MaixnerF.et al. (2012). New insights into the Tyrolean Iceman's origin and phenotype as inferred by whole-genome sequencing. Nat. Commun. 3:698. 10.1038/ncomms1701
25
KennedyA. G. (2013). Differential diagnosis and the suspension of judgment. J. Med. Philos. 38, 487–500. 10.1093/jmp/jht043
26
KlempnerM. S.HuL. T.EvansJ.SchmidC. H.JohnsonG. M.TrevinoR. P.et al. (2001). Two controlled trials of antibiotic treatment in patients with persistent symptoms and a history of Lyme disease. N. Engl. J. Med. 345, 85–92. 10.1056/NEJM200107123450202
27
LeeD. J.VielmeyerO. (2011). Analysis of overall level of evidence behind infectious diseases society of america practice guidelines. Arch. Intern. Med. 171, 18–22. 10.1001/archinternmed.2010.482
28
LeeS. H.VigliottiJ. S.VigliottiV. S.JonesW.ShearerD. M. (2014). Detection of Borreliae in archived sera from patients with clinically suspect Lyme disease. Int. J. Mol. Sci. 15, 4284–4298. 10.3390/ijms15034284
29
LewisK. (2007). Persister cells, dormancy and infectious disease. Nature5, 48–56. 10.1038/nrmicro1557
30
Lopes de CarvalhoI.FonsecaJ. E.MarquesJ. G.UllmannA.HojgaardA.ZeidnerN.et al. (2009). Vasculitis-like syndrome associated with Borrelia lusitaniae infection. Clin. Rheumatol. 27, 1587–1591. 10.1007/s10067-008-1012-z
31
MakhaniN.MorrisS. K.PageA. V.BrophyJ.LindsayL. R.BanwellB. L.et al. (2011). A twist on Lyme: the challenge of diagnosing European Lyme neuroborreliosis. J. Clin. Microbiol. 49, 455–457. 10.1128/JCM.01584-10
32
MantovaniE.CostaI. P.GauditanoG.BonoldiV. L. N.HiguchiM. L.YoshinariN. H. (2007). Description of Lyme disease-like syndrome in Brazil. Is it a new tick borne disease or Lyme disease variation?Braz. J. Med. Biol. Res. 40, 443–456. 10.1590/S0100-879X2006005000082
33
MarangoniA.SparacinoM.CavriniF.StorniE.MondardiniV.SambriV.et al. (2005). Comparative evaluation of three different ELISA methods for the diagnosis of early culture-confirmed Lyme disease in Italy. J. Med. Microbiol. 54, 361–367. 10.1099/jmm.0.45853-0
34
MargosG.PiesmanJ.LaneR. S.OgdenN. H.SingA.StraubingerR. K.et al. (2014). Borrelia kurtenbachii sp. nov.: a widely distributed member of the Borrelia burgdorferi sensu lato species complex in North America. Int. J. Syst. Evol. Microbiol. 64, 128–130. 10.1099/ijs.0.054593-0
35
MavinS.EvansR.MilnerR. M.ChattertonJ. M. W.Ho-YenD. O. (2009). Local Borrelia burgdorferi sensu stricto and Borrelia afzelii strains in a single mixed antigen improves Western blot sensitivity. J. Clin. Pathol. 62, 552–554. 10.1136/jcp.2008.063461
36
MavinS.MilnerR. M.EvansR.ChattertonJ. M. W.JossA. W. L.Ho-YenD. O. (2007). The use of local isolates in Western blots improves serological diagnosis of Lyme disease in Scotland. J. Med. Microbiol. 56, 47–51. 10.1099/jmm.0.46793-0
37
MiklossyJ. (2012). Chronic or late Lyme neuroborreliosis: analysis of evidence compared to chronic or late neurosyphilis. Open Neurol. J. 6, 146–157. 10.2174/1874205X01206010146
38
MurgiaR.CincoM. (2004). Induction of cystic forms by different stress conditions in Borrelia burgdorferi. APMIS112, 57–62. 10.1111/j.1600-0463.2004.apm1120110.x
39
NicolleC. (1993). Destin des maladies infectieuses (in French), in Reedited by the Association des ed France Lafayette (Paris: Anciens Elèves de l'Institut Pasteur), 216.
40
NieldsJ. A.KvetonJ. F. (1991). Tullio phenomenon and seronegative Lyme borreliosis. Lancet338, 128–129. 10.1016/0140-6736(91)90130-H
41
OgdenN. H.MargosG.AanensenD. M.DrebotM. A.FeilE. J.HanincovaK.et al. (2011). Investigation of genotypes of Borrelia burgdorferi in Ixodes scapularis ticks collected during surveillance in Canada. Appl. Environ. Microbiol. 77, 3244–3254. 10.1128/AEM.02636-10
42
PerronneC. (2012). Lyme disease antiscience. Lancet Infect. Dis. 12, 361–362. 10.1016/S1473-3099(12)70053-1
43
PhillipsS. E.MattmanL. H.HulinskaD.MoayadH. (1998). A proposal for the reliable culture of Borrelia burgdorferi from patients with chronic Lyme disease, even from those previously aggressively treated. Infection26, 364–367. 10.1007/BF02770837
44
RizzoliA.HauffeH. C.CarpiG.Vourc'hG. I.NetelerM.RosàR. (2011). Lyme borreliosis in Europe. Eurosurveillance16, 1–8.
45
Roche-LanquetotM. O.AderF.DurandM. C.CarlierR.DefferièreH.DinhA.et al. (2008). Results of a prospective standardized study of 30 patients with chronic neurological and cognitive disorders after tick bites (in French). Med. Mal. Infect. 38, 543–548. 10.1016/j.medmal.2008.06.007
46
RudenkoN.GolovchenkoM.GrubhofferL.OliverJ. H.Jr. (2011). Updates on Borrelia burgdorferi sensu lato complex with respect to public health. Ticks Tick Borne Dis. 2, 123–128. 10.1016/j.ttbdis.2011.04.002
47
RudenkoN.GolovchenkoM.RuzekD.PiskunovaN.MallatovaN.GrubhofferL. (2009). Molecular detection of Borrelia bissettii DNA in serum samples from patients in the Czech Republic with suspected borreliosis. FEMS Microbiol. Let. 292, 274–281. 10.1111/j.1574-6968.2009.01498.x
48
SchutzerS. E.CoyleP. K.BelmanA. L.GolightlyM. G.DrulleJ. (1990). Sequestration of antibody to Borrelia burgdorferi in immune complexes in seronegative Lyme disease. Lancet335, 312–315. 10.1016/0140-6736(90)90606-6
49
SchwanT. G.AndersonJ. M.LopezJ. E.FischerR. J.RaffelS. J.McCoyB. N.et al. (2012). Endemic foci of the tick-borne relapsing fever spirochete Borrelia crocidurae in Mali, West Africa, and the potential for human infection. PLoS Negl. Trop. Dis. 6:e1924. 10.1371/journal.pntd.0001924
50
StanekG.ReiterM. (2011). The expanding Lyme Borrelia complex–clinical significance of genomic species?Clin. Microbiol. Infect. 17, 487–493. 10.1111/j.1469-0691.2011.03492.x
51
StraubingerR. K. (2000). PCR-based quantification of Borrelia burgdorferi organisms in canine tissues over a 500-day postinfection period. J. Clin. Microbiol. 38, 2191–2199.
52
StraubingerR. K.SummersB. A.ChangY. F.AppelM. J. (1997). Persistence of Borrelia burgdorferi in experimentally infected dogs after antibiotic treatment. J. Clin. Microbiol. 35, 111–116.
53
StrickerR. B.JohnsonL. (2014). Lyme disease: call for a “Manhattan Project” to combat the epidemic. PLoS Pathog. 10:e1003796. 10.1371/journal.ppat.1003796
54
StrleF.StanekG. (2009). Clinical manifestations of Lyme borreliosis. Curr. Probl. Dermatol. 37, 51–110. 10.1159/000213070
55
TagerF. A.FallonB. A.KeilpJ.RissenbergM.Ray JonesC.LiebowitzM. R. (2001). A controlled study of cognitive deficits in children with chronic Lyme disease. J. Neuropsychiatry Clin. Neurosci. 13, 500–507. 10.1176/appi.neuropsych.13.4.500
56
TveitnesD.OymarK.NatasO. (2009). Laboratory data in children with Lyme neuroborreliosis, relation to clinical presentation and duration of symptoms. Scand. J. Infect. Dis. 41, 355–362. 10.1080/00365540902787666
57
VarelaA. S.LuttrellM. P.HowerthE. W.MooreV. A.DavidsonW. R.StallknechtD. E.et al. (2004). First culture isolation of Borrelia lonestari, putative agent of Southern tick-associated rash illness. J. Clin. Microbiol. 42:1163–1169. 10.1128/JCM.42.3.1163-1169.2004
58
Vayssier-TaussatM.MoutaillerS.MicheletL.DevillersE.BonnetS.ChevalJ.et al. (2013). Next generation sequencing uncovers unexpected bacterial pathogens in ticks in Western Europe. PLoS ONE8:e81439. 10.1371/journal.pone.0081439
59
WalletF.LabaletteP.HerweghS.LoïezC.MargaronF.CourcolR. J. (2008). Molecular diagnosis of a bilateral panuveitis due to Borrelia burgdorferi sensu lato by cerebral spinal fluid analysis. J. Infect. Dis. 61, 214–215.
60
Wojciechowska-KoszkoI.MaczynskaI.SzychZ.Giedrys-KalembaS. (2011). Serodiagnosis of borreliosis: indirect immunofluorescence assay, enzyme-linked immunosorbent assay and immunoblotting. Arch Immunol. Ther. Exp. 59, 69–77. 10.1007/s00005-010-0111-0
61
WormserG. P. (2006). Early Lyme disease. N. Engl. J. Med. 354, 2794–2801. 10.1056/NEJMcp061181
62
WormserG. P.DattwylerR. J.ShapiroE. D.HalperinJ. J.SteereA. C.KlempnerM. S.et al. (2006). The clinical assessment, treatment, and prevention of Lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America. Clin. Infect. Dis. 43, 1089–1134. 10.1086/508667
63
YrjänäinenH.HytönenJ.HartialaP.OksiJ.ViljanenM. K. (2010). Persistence of borrelial DNA in the joints of Borrelia burgdorferi-infected mice after ceftriaxone treatment. APMIS118, 665–673. 10.1111/j.1600-0463.2010.02615.x
Summary
Keywords
Lyme disease, Borrelia burgdorferi, Borrelia miyamotoi, novel borreliae, diagnosis, coinfections, tick borne disease, occult infection
Citation
Perronne C (2014) Lyme and associated tick-borne diseases: global challenges in the context of a public health threat. Front. Cell. Infect. Microbiol. 4:74. doi: 10.3389/fcimb.2014.00074
Received
25 March 2014
Accepted
19 May 2014
Published
03 June 2014
Volume
4 - 2014
Edited by
Muriel Vayssier-Taussat, Institut National de la Recherche Agronomique, France
Reviewed by
Leona Gilbert, University of Jyväskylä, Finland; Josette Raymond, Université Paris Descartes, France
Copyright
© 2014 Perronne.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: c.perronne@rpc.aphp.fr
This article was submitted to the journal Frontiers in Cellular and Infection Microbiology.
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.